BMS reports CheckMate -142 data for Opdivo plus Yervoy in dMMR or MSI-H metastatic CRC

Bristol-Myers Squibb Co. (NYSE:BMY) said Opdivo nivolumab plus Yervoy ipilimumab led to an objective response rate (ORR) of 55% among 119 patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (CRC) in the Phase II CheckMate -142 trial. Data were presented at

Read the full 463 word article

User Sign In